Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» efgartigimod
efgartigimod
Aducanumab tops 2021’s biggest potential launches
Aducanumab tops 2021’s biggest potential launches
EP Vantage
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
Flag link:
Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M
Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M
Fierce Biotech
Argenx
Bayer
FDA
priority reviews
efgartigimod
ITP
Flag link:
Biotech Argenx's autoimmune phase 3 hits goals, teeing up FDA filing
Biotech Argenx's autoimmune phase 3 hits goals, teeing up FDA filing
Fierce Biotech
Argenx
efgartigimod
myasthenia gravis
Flag link:
Upcoming events – Wave takes on Huntington's and Argenx goes subcutaneous
Upcoming events – Wave takes on Huntington's and Argenx goes subcutaneous
EP Vantage
Wave Life Sciences
WVE-120101
Huntington's disease
Argenx
efgartigimod
autoimmune disease
Flag link:
